Direct-acting antiviral agents for hepatitis c virus infection

Jennifer J. Kiser, Charles Flexner

Research output: Contribution to journalReview articlepeer-review

Abstract

Two selective inhibitors of the hepatitis C virus (HCV) protease nearly double the cure rates for this infection when combined with peginterferon alfa and ribavirin. These drugs, boceprevir and telaprevir, received regulatory approval in 2011 and are the first direct-acting antiviral agents (DAAs) that selectively target HCV. During 2012, at least 30 additional DAAs were in various stages of clinical development. HCV protease inhibitors, polymerase inhibitors, and NS5A inhibitors (among others) can achieve high cure rates when combined with peginterferon alfa and ribavirin and demonstrate promise when used in combination with one another. Current research is attempting to improve the pharmacokinetics and tolerability of these agents, define the best regimens, and determine treatment strategies that produce the best outcomes. Several DAAs will reach the market simultaneously, and resources will be needed to guide the use of these drugs. We review the clinical pharmacology, trial results, and remaining challenges of DAAs for the treatment of HCV.

Original languageEnglish (US)
Pages (from-to)427-449
Number of pages23
JournalAnnual Review of Pharmacology and Toxicology
Volume53
DOIs
StatePublished - Jan 2013

Keywords

  • boceprevir
  • drug interactions
  • efficacy
  • pharmacology
  • telaprevir

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Direct-acting antiviral agents for hepatitis c virus infection'. Together they form a unique fingerprint.

Cite this